Marcaine 0.5%

Quick links

Choose a section

Quick links to important sections

Advertisements

Marcaine 0.5%

Advertisements
Advertisements

Method of action: Anesthetic, Local Anesthetic

Advertisements

Overview of Marcaine 0.5%

What is Marcaine 0.5%?

Marcaine 0.5% is a sterile, non-pyrogenic solution containing bupivacaine hydrochloride, a medication belonging to the amide-type class of local anesthetics. It is characterized by its potency and a significantly longer duration of action compared to many other local anesthetic agents.

Composition and Mechanism

The active ingredient, bupivacaine, works by stabilizing the neuronal membrane. It achieves this by inhibiting the ionic fluxes required for the initiation and conduction of nerve impulses, effectively providing a localized loss of sensation. The 0.5% concentration indicates a specific strength of the active drug, often utilized for procedures requiring prolonged sensory blockade.

Clinical Applications

Marcaine 0.5% is primarily used to produce local or regional anesthesia and analgesia. It is frequently employed in various medical settings, including:

  • Infiltration Anesthesia: Providing numbness in a specific area for minor surgical procedures.
  • Peripheral Nerve Blocks: Interrupting pain signals from a specific nerve or group of nerves.
  • Epidural Blockade: Administered into the epidural space to provide anesthesia for surgical procedures or pain management during labor and delivery.

By blocking the conduction of pain signals from a specific part of the body to the brain, Marcaine 0.5% allows for surgical and diagnostic procedures to be performed while the patient remains comfortable or conscious, depending on the clinical requirement.

Advertisements

What side effects are possible with Marcaine 0.5%?

Possible side effects and safety information

The official safety profile for Bupivacaine (the active ingredient in Marcaine 0.5%) classifies adverse reactions based on their frequency of occurrence, as documented by government regulatory agencies such as the FDA and EMA. These reactions primarily involve the Cardiovascular and Nervous Systems.


Frequency-Classified Adverse Reactions

The following are classified according to standard regulatory frequency bands:

  • Very Common (ge 1/10): Hypotension (low blood pressure), Nausea.
  • Common (ge 1/100 to < 1/10): Bradycardia (slow heart rate), Vomiting, Dizziness, Paresthesia (tingling), Headache, and Urinary retention.
  • Uncommon (ge 1/1,000 to < 1/100): Symptoms of Central Nervous System (CNS) toxicity, such as Tremor or Convulsions (seizures).
  • Rare (ge 1/10,000 to < 1/1,000): Cardiac arrest, Arrhythmias, Respiratory depression, and severe Hypersensitivity reactions.

Serious Safety Considerations

Official regulatory documents list Cardiac arrest, Convulsions/Seizures, and severe Anaphylactic reactions as serious adverse reactions. The onset of serious CNS and Cardiovascular toxicity is typically linked to rapid systemic absorption or accidental intravascular injection occurring during or immediately following the procedure.

Safety statements also address specific populations. Older adults may have an increased risk of systemic toxicity and patients with hepatic impairment may experience reduced metabolism of Bupivacaine. Furthermore, the label strictly contraindicates the use of this medicine in certain administration methods, including Intravenous Regional Anesthesia (Bier block) and Obstetrical Paracervical Block Anesthesia, due to specific documented safety concerns.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation classifies an overdose of Marcaine 0.5% (Bupivacaine HCl) as Acute Systemic Toxicity, which primarily affects the Central Nervous System (CNS) and the Cardiovascular System. This toxicity is generally dose-related and may result from excessive dosage or rapid absorption.


Documented Overdose Manifestations

System Clinical Signs and Manifestations (as documented)
Central Nervous System Early signs may include restlessness, anxiety, tremors, dizziness, tinnitus, and perioral numbness. This can progress to more severe manifestations like convulsions, unconsciousness, and respiratory arrest.
Cardiovascular System Severe toxicity may lead to bradycardia, profound hypotension, ventricular arrhythmias, cardiovascular collapse, and potentially cardiac arrest.

Regulatory Mandate for Urgent Action

Immediate medical attention is required upon the appearance of any signs of systemic toxicity. The injection must be stopped immediately if neurological or cardiac signs develop. Management for acute systemic toxicity involves prompt symptomatic and supportive treatment, including airway management, providing adequate oxygenation, and establishing full cardiovascular support, as delay in intervention can lead to severe or fatal outcomes. Prolonged observation and monitoring are required for patients who experience confirmed toxicity. No specific antidote is known; treatment is supportive. Caution is noted for use in patients with severe liver disease due to the potential for increased toxicity.

Advertisements

Therapeutic Uses of Marcaine 0.5%

What Marcaine 0.5% Treats: Main Uses and Benefits

Marcaine 0.5% is used to help provide sustained symptomatic relief by inducing a temporary loss of sensation. Its therapeutic benefit is centered on managing severe discomfort in acute clinical settings. The medication is applied for procedures requiring regional anesthesia and analgesia. It is commonly used to help with symptoms related to physical discomfort during major and minor surgical interventions, regional nerve blocks, and for obstetrical analgesia during labor and delivery.


Therapeutic Benefit in Acute Symptomatic Episodes

This medication is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to severe, acute pain that occurs during and immediately after surgical procedures, or the intense, localized discomfort found in conditions requiring regional blockade. The medication provides support that helps ease the overall symptom burden and contributes to improved comfort during the critical early recovery phase.

“This use is relevant when short-term symptomatic assistance is needed and symptoms that create noticeable physiological strain.”


Quick Fact: Relief for Severe Acute Pain

Marcaine 0.5% is commonly used to help with conditions characterized by periods of heightened symptoms, such as the acute pain in the postoperative period or during labor. It may assist with maintaining functional stability during these specialized phases.

Advertisements

Eligibility and Restrictions for Use

The eligibility profile for Marcaine 0.5% (Bupivacaine Hydrochloride Injection) is strictly defined by government regulatory documents based on patient conditions, age, and intended use.


Absolute Prohibitions (Contraindications)

Use of Marcaine 0.5% is forbidden in patients with known hypersensitivity to bupivacaine or any other amide-type local anesthetic. It is also contraindicated for specific procedures: obstetrical paracervical block anesthesia and intravenous regional anesthesia (Bier Block). Neuraxial blocks may be prohibited in patients with conditions such as septicemia or active Central Nervous System disease.


Population and Condition Restrictions

Administration is not recommended for pediatric patients younger than 12 years. Use requires caution and monitoring in patients with severe hepatic disease due to altered metabolism. Geriatric patients (65 years and over) and those with impaired cardiovascular function (such as heart block) also require special consideration. Specific formulations containing epinephrine are contraindicated in patients with conditions like thyrotoxicosis.


Developmental Status Eligibility

While contraindicated for the paracervical block, the 0.5% concentration is indicated for other forms of obstetrical anesthesia. The medicine is excreted in human milk, but the quantity is small and generally poses no risk to the nursing infant at therapeutic doses.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Bupivacaine HCl (Marcaine 0.5%) based on pharmacodynamic additive effects and specific restrictions tied to formulation type. Co-administration with other Local Anesthetics results in additive toxic effects, requiring monitoring due to the potential for combined systemic toxicity. Similarly, use with Central Nervous System (CNS) Depressants may lead to an additive depressant effect.

A critical set of interaction constraints applies only when the Bupivacaine HCl solution contains a vasoconstrictor (such as Epinephrine). Such formulations are contraindicated with Ergot-Type Oxytocic Drugs due to the formal risk of severe, prolonged hypertension. Furthermore, co-administration of the vasoconstrictor-containing formulation with Monoamine Oxidase Inhibitors (MAOI) or Tricyclic Antidepressants (TCA) may also result in severe prolonged hypertension. Concurrent exposure to agents known to cause methemoglobinemia increases the documented risk of developing methemoglobinemia.

Regarding pharmacokinetic considerations, caution is officially noted for administering repeat doses to patients with Severe Hepatic Disease. This is due to the potential for slower metabolic clearance, which can lead to drug accumulation and an increased risk of systemic toxicity. No mandatory timing separation rules for administration with other medicines are explicitly documented in the official labeling.

Advertisements

Mechanism of Action

The mechanism of action for Marcaine 0.5% (bupivacaine) involves the direct blockade of electrical transmission in nerve cells, focusing on three key mechanistic domains.

Blocking the Nerve Impulse at the mathbfNa^+ Channel

Bupivacaine’s primary molecular target is the voltage-gated sodium channel (NaV). The ionized form of the molecule physically blocks the channel pore from the intracellular side, halting the influx of sodium ions (Na^+) and preventing the depolarization required to propagate a nerve impulse. This core action results in the inhibition of afferent (sensory) and efferent (motor) nerve conduction.

Differential Dampening of Peripheral Neural Pathways

The mechanism describes the selectivity of signal interruption across different nerve fiber types (e.g., small, unmyelinated mathbfC fibers versus large, myelinated mathbfAalpha fibers). This differential effect on fiber types results in the modulation of nociceptive signaling and contributes to the characteristics of the resulting physiological response.

Constraints of the Ionized-Molecule Cascade

This domain focuses on the physiochemical constraints of the drug’s access: the mathbfpH-dependent cascade requires the drug to be in its un-ionized form to cross the nerve membrane before converting back to its ionized form to bind the channel. These constraints regulate the degree of channel blockade achieved by limiting access to the intracellular target.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Marcaine 0.5%

The administration of Marcaine 0.5% (Bupivacaine Hydrochloride) is restricted to parenteral injection for the purpose of regional or local loss of sensation. Approved routes include Peripheral Nerve Block, Caudal Block, Lumbar Epidural Block, and Local Infiltration. The standard solution is specifically not for intrathecal (spinal) use.

Usage involves carefully calculated and adjusted dosages based on the specific procedure and the area of administration. Typical adult dose ranges for the 0.5% concentration may fall between 25 mg and 175 mg for Peripheral Nerve Blocks. The administration is generally a single, procedure-related dose, though repeat doses may be given up to once every three hours. The maximum total dose administered over any 24-hour period must not exceed 400 mg.

The medicine is required to be administered by or under the supervision of experienced clinicians using the lowest effective dosage. Procedural guidelines mandate that the solution must be visually inspected and confirmed to be clear and colorless prior to injection. For major blocks, such as epidurals, the drug must be injected slowly in fractional (incremental) doses to avoid rapid absorption.

The official labeling restricts the use of solutions containing antimicrobial preservatives (found in multi-dose vials) for both caudal and epidural anesthesia. Dosage adjustments are also required for certain groups; doses for older, debilitated, or acutely ill patients must be reduced, and the use of the medicine in children younger than 12 years is generally not recommended.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Marcaine 0.5%


Evidence for Regional Anesthesia and Procedures

The research examining Marcaine 0.5% (Bupivacaine HCl) for regional anesthesia has primarily used Randomized Controlled Trials (RCTs) and controlled clinical studies. This research was evaluated in settings exploring sensory blockade, such as nerve blocks or epidural administration for surgical and diagnostic procedures. Researchers focused on measuring outcomes related to physical discomfort by timing the onset and the duration of the sensory block.

The findings describe patterns observed in the studies regarding the duration of the sensory block and the subsequent interval before the return of sensation. However, the evidence is generally focused on the acute period surrounding the procedure. Data show patterns related to the 0.5% concentration being associated with a lower degree of muscle relaxation in some surgical contexts, which is a research limitation.


Evidence for Acute Symptomatic Pain Management

Research exploring this medicine was studied for its use during outcomes capturing phases of heightened symptom activity, such as severe, acute pain after surgery. These studies measured the total amount of strong pain medication (opioids) that patients requested following surgery and monitored patient-reported outcomes describing perceived discomfort.

The findings indicate patterns related to the length of the time interval before patients requested additional pain medication. The data show patterns related to the drug's inherent properties, specifically its limited duration of effect, meaning that continuous delivery systems can be necessary to maintain observed patterns of pain medication request.


What Is Still Uncertain About the Research for Marcaine 0.5%

The research base for the medicine's primary acute uses suggests several areas of uncertainty. Long-term effects are not fully established because the follow-up durations were limited in most key studies, providing little insight into extended functional recovery. Additionally, the evidence is limited for the safe and predictable use of this medicine in the youngest children, and data for certain groups remain insufficient to draw broad conclusions for the entire pediatric population.

Key Studies & References

  1. Label: Bupivacaine Hydrochloride Injection, Solution (Marcaine, Sensorcaine) - FDA Prescribing Information
  2. WHO Model List of Essential Medicines - Bupivacaine (for general utility and widespread use)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Marcaine 0.5% (FAQ)


Q: What is the main reason doctors use Marcaine 0.5%?

Marcaine 0.5% is an essential medicine used primarily to achieve a controlled, temporary loss of sensation. According to official information, its core purpose is the inhibition of pain signal transmission by acting directly on nerve fibers. This action makes it foundational to the practice of regional anesthesia.


Q: Is Marcaine 0.5% the same as bupivacaine?

Yes, Marcaine is a brand name for the medicine whose core active ingredient is Bupivacaine Hydrochloride ( Bupivacaine HCl). It is officially classified as an amino amide-type local anesthetic.


Q: How long does the numbing effect of Marcaine 0.5% typically last?

Official research has examined the duration of the resulting sensory block, noting that the drug is considered relatively long-acting. The specific duration of the numbing effect may vary depending on factors such as the concentration used and the site of administration.


Q: Can Marcaine 0.5% be used for pain after surgery?

Official research has included studies on the use of Marcaine 0.5% for managing acute pain following surgery. These studies help evaluate patient outcomes related to discomfort and the subsequent need for additional pain medication.


Q: What are the most common patient-reported side effects of Marcaine?

According to official safety information, the most common adverse reactions, classified as Very Common (ge 1/10), are Hypotension (low blood pressure) and **Nausea. Monitoring for these effects is a standard procedure during and after administration.


Q: Is a headache common after receiving Marcaine 0.5%?

Yes, a Headache is officially classified as a Common side effect, meaning it may occur in ge 1/100 to < 1/10 patients. This is one of several officially listed common central nervous system effects.


Q: How quickly does Marcaine 0.5% start working after it's given?

Controlled clinical studies for Marcaine 0.5% focused on measuring the specific onset time of the sensory block following administration. The time it takes for the sensory block to begin working depends on the specific injection site and procedure.


Q: Does Marcaine 0.5% contain adrenaline or epinephrine?

Marcaine 0.5% is available in standard formulations that do not contain a vasoconstrictor and in formulations that do contain one, such as Epinephrine. The official restrictions and storage requirements differ based on the presence of Epinephrine.


Q: Is Marcaine 0.5% used only for local numbing or for larger areas too?

Marcaine 0.5% is approved for use in both small and large areas. Officially approved routes include both Local Infiltration (for small areas) and various forms of regional anesthesia, such as Peripheral Nerve Block and Lumbar Epidural Block, which target larger nerve regions.


Q: Can Marcaine 0.5% cause an allergic reaction?

Yes, official documents list severe Hypersensitivity reactions (allergic reactions) as rare adverse events. The medicine is contraindicated (not permitted) in patients with a known hypersensitivity or allergy to bupivacaine or any other amide-type local anesthetic.


Q: Can patients with heart conditions receive Marcaine 0.5%?

Regulatory documents state that patients with impaired cardiovascular function require special consideration and careful monitoring. Furthermore, the medicine is contraindicated (absolutely prohibited) for certain specific procedures due to cardiovascular safety concerns.


Q: Is this medicine used for nerve blocks?

Yes, the official administration guidelines list Peripheral Nerve Block as one of the key approved routes for receiving Marcaine 0.5%. It is specifically designed to block sensation along a targeted nerve pathway.


Q: What kind of studies support the use of Marcaine 0.5%?

The research base supporting the use of Marcaine 0.5% has primarily utilized Randomized Controlled Trials (RCTs) and controlled clinical studies. These studies have examined outcomes related to sensory blockade and pain management following procedures.


Q: Is it safe for older adults (seniors) to be given Marcaine 0.5%?

Official guidelines indicate that doses for this group require special care. Doses for older adults (65 years and over) and acutely ill patients must be reduced due to potential increased risk of systemic toxicity. This patient group requires special consideration during administration.


Q: Does Marcaine 0.5% affect blood pressure?

Yes, official safety information classifies Hypotension (low blood pressure) as a Very Common (ge 1/10) adverse reaction. Monitoring of blood pressure is a standard safety measure during and after administration.


Q: What should a patient know about Marcaine 0.5% if they are pregnant?

The medicine is contraindicated for obstetrical paracervical block anesthesia but is indicated for other forms of obstetrical anesthesia, such as epidurals. While it is excreted in human milk, the quantity is typically small and generally poses no risk to the nursing infant.


Q: Can Marcaine 0.5% be used on children?

The medicine is generally not recommended for pediatric patients younger than 12 years. Official research indicates that the evidence is limited for the safe and predictable use of this medicine in the youngest children.


Q: Why does this medicine sometimes cause a temporary feeling of dizziness?

Dizziness is officially classified as a common adverse reaction, along with other central nervous system symptoms like headache or tremor. These effects are related to the drug's core mechanism, which blocks electrical signaling in nerve cells.


Q: Does the numbing spread to a wider area than where it was injected?

The intended spread depends entirely on the procedure. The administration can be limited to a small area for Local Infiltration, or it can be targeted to block sensation across a wider regional area, such as for a Peripheral Nerve Block.


Q: Is Marcaine 0.5% associated with temporary muscle weakness?

Yes, the drug’s mechanism of action involves the inhibition of efferent (motor) nerve conduction, meaning it can affect muscle movement. Official research indicates that the 0.5% concentration is generally associated with a lower degree of muscle relaxation in certain surgical contexts.


Q: Are there any specific medical conditions where this drug is officially not recommended?

Yes, official contraindications include known hypersensitivity to bupivacaine, certain procedures (e.g., Bier Block), and conditions such as septicemia or active Central Nervous System disease for neuraxial blocks.


Q: How does Marcaine 0.5% affect the body's pain signals?

The drug works by blocking the influx of sodium ions ( Na^+) through the sodium channel in nerve cells. This action prevents the electrical signal required to propagate the nerve impulse, resulting in inhibition of afferent (sensory) nerve conduction.


Q: Why do some people call it by a different name like bupivacaine hydrochloride?

Bupivacaine Hydrochloride ( Bupivacaine HCl) is the official name of the medicine’s core active ingredient. Marcaine is one of the brand names under which this medicine is commonly sold.


Q: Does the manufacturer list any major warnings for Marcaine 0.5%?

Yes, official documents list serious adverse reactions such as Cardiac arrest, Convulsions/Seizures, and severe Anaphylactic reactions. The label also lists specific procedures that are contraindicated (forbidden) due to safety concerns.


Q: Is it common for studies to compare Marcaine to a placebo?

Official research documents confirm that the medicine has been examined in Randomized Controlled Trials (RCTs) and controlled clinical studies. These are standard research formats used to evaluate drug effectiveness, often involving comparison groups such as placebo or active controls.


Q: Can patients with liver or kidney issues use Marcaine 0.5%?

Official regulatory documents note that repeat doses should be administered with caution to patients with Severe Hepatic Disease (liver issues). This is due to the potential for slower metabolic clearance, which can increase the risk of toxicity. Guidance specific to kidney function is not explicitly noted in the existing restrictions.


Q: Is the effect of Marcaine 0.5% reversible?

The primary purpose of the medicine is to achieve a controlled, temporary loss of sensation. The effects conclude naturally as the physiochemical constraints limiting the drug's binding to the nerve channel resolve, allowing the nerve impulse to return.


Q: How does the numbing wear off?

The numbing effect wears off as the constraints of the drug's ionized-molecule cascade resolve within the nerve cell. This natural process gradually limits the drug's access to the sodium channel, allowing the nerve cells to resume normal signal propagation.


Q: Are there any known severe adverse events associated with Marcaine 0.5%?

Yes, official regulatory documents list Cardiac arrest, Convulsions/Seizures, and severe Anaphylactic reactions as serious adverse reactions. These events are linked to safety concerns involving systemic absorption and are documented in the official safety information.


Q: What is the official purpose of the preservative-free version of Marcaine 0.5%?

Regulatory guidelines strictly restrict the use of solutions containing antimicrobial preservatives for certain procedures. This means the preservative-free formulation must be used for administration via both caudal and epidural anesthesia.


Q: Why is careful placement of the injection important for this medicine?

Careful placement and slow injection are crucial safety measures. Procedural guidelines mandate that the drug be injected slowly in fractional (incremental) doses to avoid rapid systemic absorption or accidental intravascular injection, which is linked to the onset of serious toxicity.


Q: Does the duration of pain relief change depending on where it's injected?

The dosage administered must be based on the specific procedure and the site of administration, such as a Peripheral Nerve Block versus a Lumbar Epidural Block. This reflects that the injection location influences the expected duration and quality of the effect.


Q: Can Marcaine 0.5% be used in labor and delivery settings?

The 0.5% concentration is generally used in obstetrics but has specific prohibitions. It is contraindicated for obstetrical paracervical block anesthesia but is officially indicated for other forms of obstetrical anesthesia (like epidurals).


Q: Are there different forms of Marcaine besides the injection solution?

The medicine is officially supplied only as a sterile aqueous solution for injection. The active ingredient is formulated for parenteral administration (injection into or around nerve tissues) and is not available in topical or oral forms.


Q: What is meant by the 'duration of action' for Marcaine 0.5%?

The term refers to the drug's classification as a relatively long-acting agent. Research focuses on measuring the time interval between administration and the return of sensation. This property makes it suitable for extended pain control.


Q: What are the eligibility criteria for receiving this medicine?

Eligibility is strictly defined by official regulatory documents based on patient conditions and age restrictions. For instance, it is forbidden for patients with known hypersensitivity to the drug and generally not recommended for children under 12 years of age.


Q: Is it possible to receive too much Marcaine 0.5%?

Yes, official documents define limits to prevent toxicity. The maximum total dose administered over any 24-hour period must not exceed 400 mg, reflecting the regulatory limit for the adult dosage.


Q: Are there any official documents describing contraindications for Marcaine?

Yes, official regulatory documents define Absolute Prohibitions (Contraindications) for use in patients with known hypersensitivity to the drug and for specific procedures like intravenous regional anesthesia (Bier block). These prohibitions are mandatory considerations prior to administration.


Q: Why might a doctor choose Marcaine over another numbing agent?

Official documents describe Bupivacaine as a synthetic compound distinguished by its relatively long-acting properties. This feature often makes it the agent of choice for procedures that require sustained pain control.


Q: How does the drug's effect relate to the nervous system?

The drug works by blocking electrical transmission in nerve cells to inhibit sensory and motor signals. Therefore, its intended effect and potential side effects, such as dizziness or tremor, primarily involve the Central and Peripheral Nervous Systems.


Q: Is it common for people to misunderstand the term 'regional anesthesia'?

Official documents describe this medicine as foundational to the practice of regional anesthesia. This approach provides a targeted method of managing discomfort by numbing a specific body area without impacting the patient's consciousness or systemic functions.


Q: What information do official sources provide on how well Marcaine works?

Official studies evaluate the drug's performance by measuring outcomes related to the management of physical discomfort. These measurements include timing the onset and duration of the sensory block and monitoring the need for additional pain medication (opioids) after surgery.


Q: Can patients with known sensitivities to local anesthetics use Marcaine 0.5%?

No. Use of Marcaine 0.5% is forbidden in patients with known hypersensitivity (severe sensitivity) to bupivacaine or any other amide-type local anesthetic. Disclosure of any prior drug sensitivities is required for safety.


Q: Why is the drug given by a healthcare professional only?

The medicine is required to be administered by or under the supervision of experienced clinicians. This is due to the safety need to ensure proper dosage and adherence to critical procedural guidelines related to avoiding rapid systemic absorption or accidental intravascular injection.


Q: Does the numbing agent affect other sensations besides pain?

Yes. The core action of the medicine results in the inhibition of afferent (sensory) and efferent (motor) nerve conduction. This means that in the targeted area, it affects both the ability to feel sensation and the ability to move the muscles.


Q: Are there specific safety classifications for Marcaine 0.5% during pregnancy?

The medicine is contraindicated for obstetrical paracervical block anesthesia but is indicated for other forms of obstetrical anesthesia. While it is excreted in human milk, the quantity is typically small and generally poses no risk to the nursing infant.


Q: What are the general expectations for recovery after the effect wears off?

The medicine is designed to achieve a temporary loss of sensation, and normal function is expected to return after the effect resolves. However, official research notes that the follow-up durations were limited in most key studies, providing little insight into extended functional recovery.


Q: Is Marcaine 0.5% available over the counter?

No. Marcaine 0.5% is a potent, prescription-only medicine and must be administered by or under the supervision of a licensed healthcare professional.

Advertisements

How should Marcaine 0.5% be stored and disposed of?

How to Store and Dispose of Marcaine 0.5%

The official labeling defines specific conditions for storing and handling Marcaine 0.5% (Bupivacaine Hydrochloride).

Storage Category Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F), with permitted excursions.
Environmental Protection Solutions containing epinephrine must be protected from light.
Prohibited Handling Solutions containing epinephrine must not be autoclaved.
Container Integrity The solution must be visually inspected to be clear and colorless; do not use if discolored or contains precipitate.
Disposal Any unused portion remaining in a single-dose container must be discarded immediately after initial use.

These storage conditions are mandated by regulatory agencies to ensure the solution's stability and integrity. The required temperature and protection from light (for epinephrine formulations) are critical to maintaining the drug's quality.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Marcaine 0.5% found in:

A-Z Index: